ClinicalTrials.gg
Status unknownNCT03290235Updated Dec 12, 2017

Extension Study of Pegylated Somatropin to Treat Growth Retardation Caused by Endogenous Growth Hormone Deficiency in Children

A Phase 4 interventional study of PEG-somatropin in Growth Retardation, sponsored by Changchun GeneScience Pharmaceutical Co., Ltd.. Status unknown at 1 site in China. Open to participants aged 42 Months to 15 Years. Per ClinicalTrials.gov, last updated 2017-12-12.

Sponsored by Changchun GeneScience Pharmaceutical Co., Ltd. · Phase 4, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Sep 2017), so the status shown — last known as Recruiting — may be out of date.

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Mar 2017, registered Sep 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
1,500
Allocation
Non-randomized
Ages
42 Months to 15 Years
Sex
All
01

Study summary

  1. To further evaluate the safety and efficacy of PEG-Somatropin in the treatment of children with growth hormone deficiency for a relatively long period
  2. To explore the factors influencing the efficacy of PEG-Somatropin and to establish the height prediction model based on Chinese children with short stature, and to provide the basis and guidance for standard and reasonable long-term clinical application of PEG-Somatropin.
02

Conditions studied

  • Growth Retardation
03

In context

Lead sponsor

Changchun GeneScience Pharmaceutical Co., Ltd. is the lead sponsor of 112 studies on the registry; 48 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
42 Months to 15 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children has completed all visits and therapy in previous phase IV study;
  • Investigators evaluate subjects could continue growth hormone therapy;
  • Subjects is willing and able to cooperate to complete scheduled visits, treatment plans and laboratory tests and other procedures, to sign .

Exclusion criteria

Exclusion Criteria:

  • Children with epiphyseal closure;
  • Children is near the adule final height, that is, growth rate≤ 2 cm / year or bone age ≥ 14 years old for girls, bone age ≥ 16 years old for boys;
  • Dysfunction of liver and kidney (> 2 times the , Cr> upper limit of normal);
  • Patients with known to PEG-Somatropin or Somatropin or any other components of the study product;
  • Patients with severe cardiopulmonary or hematological diseases, a current or past history of malignant tumors, immunodeficiency diseases, or mental diseases;
  • Patients with diabetics;
  • Patients with congenital bone dysplasia or scoliosis;
  • Patients took drugs that would influence the efficacy and safety of PEG-Somatropin after phase IV study and before screening for this extension study;
  • Other conditions in which the investigator preclude enrollment into the study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,500 participants (estimated)

Study arms

  • Experimental
    PEG-somatropin-1

    Dosage 0.2mg/kg/w

    Drug: PEG-somatropin

  • Experimental
    PEG-somatropin-2

    Dosage 0.1-0.2mg/kg/w

    Drug: PEG-somatropin

Interventions

  • Pegylated somatropin, injection, 54IU/9.0mg/1.0ml/kit

    Also known as: Jintrolong®

06

What researchers measure

Primary outcomes

  1. Ht SDSca (Height standard deviation score for chronological age)

    Calculated by dividing the difference between the actual height of a patient and the mean height of the population for that chronological age by the standard deviation (SD) of the height of the population for that chronological age

    Time frame: Baseline, every 13 weeks until 130 weeks

Secondary outcomes

  1. Ht SDSBA (Height standard deviation score for bone age)

    Time frame: Baseline, every 13 weeks until 130 weeks

  2. Yearly growth velocity

    Time frame: Baseline, every 13 weeks until 130 weeks

  3. IGF-1 SDS (Standard deviation score of insulin-like growth factor-1)

    Time frame: Baseline, every 13 weeks until 130 weeks

  4. Bone age

    Time frame: Baseline, 26 weeks, 52 weeks, 78 weeks, 104 weeks, 130 weeks

  5. Near final height for some subjects

    When yearly growth velocity of some subject is no more than 2cm/year.

    Time frame: Baseline, every 13 weeks until 130 weeks

07

Study locations

1 of 1 sites recruiting
  • TongJi hospital affiliated to TongJi medical college of HuaZhong university of Science & Teconology
    Wuhan, Hubei, China
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2017 (actual). Primary completion is estimated for Oct 2020, 43 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 19, 2017
First posted
Sep 21, 2017
StartActual
Mar 1, 2017
Primary completionEst.
Oct 2020
CompletionEst.
Sep 2021
Last update
Dec 12, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 12, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03290235
Responsible party
Sponsor
First posted
Sep 21, 2017
Start date
Mar 1, 2017
Primary completion
Oct 2020 (estimated)
Completion
Sep 2021 (estimated)
Last update
Dec 12, 2017

Study contacts

Xiaohua Feng
Contact
fengxiaohua@gensci-china.com
0431-85170552

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Human Growth Hormone

Start the discussion